Publications by authors named "G D Di Giovanni"
New Approaches to Lipoproteins for the Prevention of Cardiovascular Events.
J Atheroscler Thromb
December 2024
Article Synopsis
- Atherosclerotic cardiovascular disease (ASCVD) is a major global health issue, with high levels of low-density lipoprotein cholesterol (LDL-C) linked to increased cardiovascular risk.
- Numerous studies confirm that lipid-lowering therapies (LLT) are effective; however, there is a gap between guidelines and actual clinical practice regarding LDL-C targets.
- The review suggests new strategies beyond traditional LDL-C management, such as combination therapies and emerging drugs, while also introducing the potential use of polygenic risk scores for personalized treatment approaches in ASCVD prevention.
After the normalization of social media in the Public Administration, they have become crucial to increasing citizen satisfaction. Alexandria Hospital has created a compliant website and an active presence on Facebook, Instagram, LinkedIn, X and YouTube. The main objectives of the "True or False" campaign are to educate the public on health issues, fight misinformation and evaluate knowledge on prevention.
View Article and Find Full Text PDFThe initiative "Le parole della ricerca," launched in 2021, aims to enhance public understanding of health research through digital communication, using visual storytelling and local influencers. The project simplified complex research terms, linked to the DAIRI's activities, into 20 key concepts, illustrated by Gastini, and shared through social media. This campaign involved professionals explaining their work with the support of art, increasing public engagement.
View Article and Find Full Text PDFBackground: Low-dose colchicine reduces the risk of cardiovascular events after myocardial infarction (MI). The purpose of this study was to assess the effect of colchicine post-MI on coronary plaque morphology in non-culprit segments by optical coherence tomography (OCT).
Methods And Results: COCOMO-ACS was a double-blind, placebo-controlled trial that randomized 64 patients (median age 61.